Stockscreener 앱 받기
15.75
0.57%
0.09
시간 외 거래:
15.75
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $32.00 - MarketBeat
Needham raises Kalvista Pharmaceuticals stock price target on Ekterly launch success - Investing.com
KalVista Pharmaceuticals (KALV): Needham Raises Price Target to $32 | KALV Stock News - GuruFocus
Millennium Management LLC Acquires Additional Shares in KalVista Pharmaceuticals - GuruFocus
KalVista Pharmaceuticals Inc 4XC1 Stock Analysis and ForecastTrading Volume Trends & No Fee. No Catch. Just Smart Investment Ideas - earlytimes.in
2025 Drug Launches Underscore Commercial Headwinds For New Products - Citeline News & Insights
How KalVista Pharmaceuticals Inc. (4XC1) stock moves in volatile trading sessionsPrice-to-Book Ratio Updates & Buy Sell Timing Alerts - bollywoodhelpline.com
Precision Trading with Kalvista Pharmaceuticals Inc. (KALV) Risk Zones - Stock Traders Daily
KalVista Pharmaceuticals (NASDAQ:KALV) Trading 5.1% HigherShould You Buy? - MarketBeat
KalVista Pharmaceuticals, Inc.Common Stock (NQ: KALV - FinancialContent
KalVista Pharmaceuticals (KALV) Gains Approval for EKTERLY in Ja - GuruFocus
Japan approves KalVista’s oral HAE treatment Ekterly By Investing.com - Investing.com Canada
KalVista (KALV) Gains Approval for Ekterly in Japan - GuruFocus
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (KALV) Movement - Stock Traders Daily
Will KalVista Pharmaceuticals Inc. stock attract ESG investors2025 Sector Review & Smart Money Movement Tracker - Улправда
KalVista Pharmaceuticals Earnings Notes - Trefis
KalVista Shares Navigate Post-Rally Consolidation Phase - AD HOC NEWS
Sentiment Review: How KalVista Pharmaceuticals Inc. (4XC1) stock expands through international marketsTrade Risk Assessment & Stepwise Swing Trade Plans - Улправда
Why KalVista Pharmaceuticals Inc. stock is favored by pension funds2025 Bull vs Bear & Free Community Consensus Stock Picks - DonanımHaber
Can KalVista Pharmaceuticals Inc. stock outperform in 2025 bull marketJuly 2025 Movers & Free Fast Entry Momentum Trade Alerts - DonanımHaber
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV) and Novan (NOVN) - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 1-Year HighHere's Why - MarketBeat
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $898,000 Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Stempoint Capital LP Cuts Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Discipline and Rules-Based Execution in KALV Response - news.stocktradersdaily.com
KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $120,423.94 in Stock - MarketBeat
Possible Bearish Signals With KalVista Pharmaceuticals Insiders Disposing Stock - simplywall.st
Pharvaris surges, pulling KalVista out of a slump, on promising new HAE treatment - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Receives Buy Rating from Needham & Company LLC - MarketBeat
KalVista Pharmaceuticals, Inc. $KALV Shares Purchased by Stonepine Capital Management LLC - MarketBeat
Saturn V Capital Management LP Sells 192,267 Shares of KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Schroder Investment Management Group Has $6.27 Million Stock Holdings in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals Executive Sells Shares to Cover Tax Obligations - TradingView
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
KalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 15%Here's What Happened - MarketBeat
Panagora Asset Management Inc. Grows Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals (KALV) Rating Reiterated by Needham | K - GuruFocus
KalVista Pharmaceuticals (KALV) to Release Quarterly Earnings on Thursday - MarketBeat
Pharvaris’s Phase III HAE Data Position Deucrictibant For 2026 NDA Filing - Citeline News & Insights
Kalvista stock price target maintained at $30 by TD Cowen amid competitor data - Investing.com Nigeria
Biotechs Duke It Out In A Genetic Disease — And Both Surge - Investor's Business Daily
Pharvaris’ oral deucrictibant hits endpoints in acute HAE trial - BioWorld MedTech
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Sahm
Why pension funds invest in KalVista Pharmaceuticals Inc. (4XC1) stockWeekly Profit Analysis & High Conviction Buy Zone Alerts - Newser
Will KalVista Pharmaceuticals Inc. (4XC1) stock profit from automation waveJuly 2025 Review & Safe Capital Investment Plans - Newser
KalVista Pharmaceuticals (KALV) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How KalVista Pharmaceuticals Inc. stock reacts to inflationary pressures2025 EndofYear Setup & Free High Return Stock Watch Alerts - Newser
Is KalVista Pharmaceuticals Inc. stock a contrarian buyJuly 2025 Price Swings & Verified Momentum Stock Alerts - Newser
KalVista Pharmaceuticals sees $967,144 in stock purchases by Venrock - Investing.com Nigeria
2.52%
0.07%
자본화:
|
볼륨(24시간):